Health Care Archives - Page 36 of 478

2 minute read

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

April 23, 3:00 PM

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

BNTX

2 minute read

Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape

By Vandana Singh

April 23, 2:55 PM

Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia.

ANRO

2 minute read

Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder

By Vandana Singh

April 23, 1:28 PM

Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in sales.

NBIX

1 minute read

Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic

By Vandana Singh

April 23, 12:44 PM

Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth.

DGX

2 minute read

This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain

By Jelena Martinovic

April 23, 10:24 AM

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA, for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.

CSE:INNO

1 minute read

Why Is Life Science-Focused Danaher Trading Higher On Tuesday?

By Vandana Singh

April 23, 10:13 AM

Danaher Corp's Q1 sales beat expectations despite a Y/Y decrease. Rainer Blair, CEO, highlights strong revenue, earnings, and cash flow. Biotech sales dip, while life sciences and diagnostics segments see slight growth. Q2 sales are expected to decline.

DHR

2 minute read

FDA Approves ImmunityBio’s Bladder Cancer Drug, Stock Rallies

By Vandana Singh

April 23, 9:54 AM

FDA approves ImmunityBio's Anktiva plus Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer. Anktiva shows promising complete response rates and duration exceeding 24 months.

IBRX

1 minute read

FDA Rejects Approval Of Abeona Therapeutics’ Skin Disorder Treatment, Shares Sink

By Vandana Singh

April 23, 9:43 AM

Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Manufacturing and Controls requirements.

ABEO

2 minute read

Novartis Stock Gains On European Drugmaker’s Q1 Earnings Surprise, Lifts Annual Outlook

By Vandana Singh

April 23, 8:25 AM

Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.

BMY

2 minute read

US Supreme Court Declines To Hear Vanda Pharmaceuticals’ Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz

By Vandana Singh

April 22, 2:37 PM

"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."

TEVA